Imagine a world where there is no donor organ shortage,
victims of spinal cord injuries can walk and weakened hearts are successfully
replaced; this is the future of regenerative medicine, as outlined by the
National Institute of Health. To obtain the massive promises of this
revolutionary treatment option, however, it is necessary to successfully
overcome the barriers associated with immune response, which have, to this
point, severely hampered the advancement of cell replacement therapies.
International Stem Cell Corporation (OTCQB: ISCO), through the continued
development of its groundbreaking parthenogenesis stem cell technology, is
addressing this limitation, potentially unlocking the door to significant
advances in the field of regenerative medicine.
Parthenogenesis utilizes unfertilized human eggs to create
pluripotent parthogenetic stem cells (hpSC) that can be immune-matched to
millions of people. According to the company’s data, a relatively small number
of hpSC lines could provide sufficient immune-matched cells to cover a large
percentage of the world’s population, effectively minimizing the effects of autoimmune
rejection and allowing for continued research into the massive potential upside
of stem cell therapy. Unlike embryonic stem cells, which require the
destruction of a human embryo, hpSC treatment also avoids many of the ethical
issues commonly associated with stem cell research.
ISCO has identified a collection of potential diseases and
conditions that could be effectively treated using its hpSCs, but the company’s
leading indication is for the treatment of Parkinson’s disease. According to
the National Parkinson Foundation, Parkinson’s disease is the 14th leading
cause of death in the United States, and an estimated four to six million
people suffer from the condition worldwide. Currently, there is no cure and
limited treatment options for the disease, creating a significantly underserved
market within the pharmaceutical industry.
“In the first quarter of 2015 we completed all the necessary
preclinical studies of our Parkinson’s program and formally submitted our
application to begin the first clinical study of this novel approach to
treating this debilitating disease in humans,” stated Dr. Andrey Semechkin,
Chief Executive Officer of ISCO. “We continue to expect to make significant
progress during the rest of 2015 towards our goal of providing a viable
treatment option for people with Parkinson’s disease.”
During preclinical studies, ISCO has demonstrated the safety
and efficacy of treating Parkinson’s disease symptoms in animals with
transplanted human parthenogenetic neural stem cells. Moving forward, the
company will seek to begin its Phase I/IIa clinical studies through its
wholly-owned subsidiary, Cyto Therapeutics Pty Ltd. For prospective
shareholders, ISCO’s continued progression with preclinical and clinical
studies makes the company an intriguing investment opportunity in the months to
come.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment